Cipla

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Cipla Limited
Public
Traded as BSE: 500087
NSE: CIPLA
BSE SENSEX Constituent
CNX Nifty Constituent
Industry Pharmaceuticals
Founded 1935
Founder Dr. K. A. Hamied
Headquarters Mumbai, Maharashtra, India
Area served
 Worldwide
Key people
 Y. K. Hamied, Chairman
Subhanu Saxena (CEO)
Products Pharmaceuticals and diagnostics
Revenue Increase ₹104.83 billion (US$1.6 billion) (2013-14)[1]
Increase ₹18.80 billion (US$280 million) (2012-13)[1]
Increase ₹13.89 billion (US$210 million) (2013-14)[1]
Total assets Increase ₹109.68 billion (US$1.6 billion) (2013-14)[1]
Total equity Increase ₹100.91 billion (US$1.5 billion) (2013-14)[1]
Number of employees
 22,036[2]
Website www.cipla.com

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India,[3][4][5] Belgium, Surrey in the European Union and Miami, Florida, in the United States; with manufacturing facilities in Goa (eight), Bengaluru (one), Baddi (one), Indore (one), Kurkumbh (one), Patalganga (one), and Sikkim (one), along with field stations in Delhi, Pune, and Hyderabad.[6] Cipla primarily develops medicines to treat cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.[7][8][9]

As of 17 September 2014, its market capitalisation was ₹517 billion (US$7.7 billion), making it India's 42nd largest publicly traded company by market value.[10][11][12]

History

It was founded by Dr. Khwaja Abdul Hamied as 'The Chemical, Industrial & Pharmaceutical Laboratories' in 1935 in Mumbai.[13][14] The name of the Company was changed to 'Cipla Limited' on 20 July 1984.[14] In the year 1985, US FDA approved the company's bulk drug manufacturing facilities.[15] Led by the founder’s son Yusuf Hamied, a Cambridge-educated chemist, the company became a global icon for its role in defying Western multinational pharmaceutical companies in order to provide generic AIDS and other drugs to treat poor people in the developing world.[16] In 1994, Cipla launched Deferiprone, the world’s first oral iron chelator.[13] In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than $350 per year per patient).[17]
In 2012, the company slashed prices of three life-saving cancer drugs by 50-64%.[18]

Products and services

Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products,[19] including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate.[2] They are the world's largest manufacturer of antiretroviral drugs[19][20]

Operations

Cipla has 34 manufacturing units in 8 locations across India and has presence in 170 countries.[21][22] Exports accounted for 48% ₹49.48 billion (US$740 million) of its revenue for FY 2013-14.[1] Cipla spent INR 517 cr. (5.4% of revenue) in FY 2013-14 on R&D activities.[1] The primary focus areas for R&D were development of new formulations, drug-delivery systems and APIs (active pharmaceutical ingredients). Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.

As on 31 March 2013, the company had 22,036 employees (out of which 2,455 were women (7.30%) and 23 were employees with disabilities (0.1%)).[2] During the FY 2013-14, the company incurred ₹12.85 billion (US$190 million) on employee benefit expenses.[1]

Listings and shareholding

The equity shares of Cipla are listed on the Bombay Stock Exchange,[23] where it is a constituent of the BSE SENSEX index,[24] and the National Stock Exchange of India,[25] where it is a constituent of the CNX Nifty.[26] Its Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.[1]

As on 30 September 2014, the promoter group, Dr. Y. K. Hamied and his family, held around 36.80% equity shares in Cipla. Around 148,000 individual shareholders held approx. 18.67% of its shares.[27] LIC is the largest non-promoter shareholder with approx. 6.45% shareholding in the company by the end of September 2013.[28]

Shareholders (as on 31-March-2014) Shareholding[27]
Promoter Group 36.80%
Foreign Institutional Investors (FII) 23.32%
Individual shareholders 19.00%
Insurance companies 06.59%
Private Corporate Bodies 04.68%
Mutual Funds and UTI 04.43%
NRI/FCB/Others 03.46%
GDRs 01.10%
Total 100.0%

Awards and recognitions

  • In 2012, Cipla received the Thomson Reuters India Innovation Award.[29]
  • Cipla won Dun & Bradstreet American Express Corporate Awards for 2006.[30]
  • In 2005, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies.[31]
  • In 1980, Cipla won Chemexcil Award for Excellence for exports.[15]

Criticism

Sale of emergency pregnancy termination pills over-the-counter

In August 2007, Cipla launched pregnancy termination pill 'i-pill'.[32] The morning-after pill was sold as the easiest way to avoid unwanted pregnancies,[33] but drew criticism as it was sold over-the-counter (hence not requiring a medical prescription) and for the probable side effects. The drug contained twice the amount of main ingredient ‘levonorgestrel’ as compared to similar drugs such as Norlevo (Win Medicare) and Ecee2 from German Remedies. One industry specialist noted that there was no evidence across the world of the drug being safe for females below 16 years of age.[citation needed] An industry insider, who also has products in oral contraception, said the amount of active ingredient in the pill could cause problem in women with high blood pressure, heart disease. The same analyst noted that the drug was not safe for people with problems such as liver disease, diabetes, migraines or asthma. Hence, if the drug was distributed over the counter then there was no practical way to prevent people with aforementioned issues or people below 16 years from buying the tablet.[34]

Sale of generic drugs

In the late 1960s, Cipla began manufacturing a new, patented drug, propranolol, and when the drug's patent holder, ICI, protested to the Indian government, the CEO of Cipla successfully lobbied the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs,and instead to allow only patents that covered methods to make drugs.[35] This change made propranolol and other patented drugs, generic and led to criticism of both India's patent laws and Cipla.[36] India reinstated patents on drugs in 2005.[35]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ 2.0 2.1 2.2 Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Cipla to buy 51% in Yemen distribution company | Business Line
  4. ↑ Cipla invests $1.5 million in Chase Pharma | Business Line
  5. ↑ Cipla gets 345 million rand South African contract | Business Line
  6. ↑ Cambridge varsity honour for Cipla chief | Business Line
  7. ↑ http://www.thehindubusinessline.com/companies/cipla-inks-coomercial-pact-with-bioquiddity-inc-for-anaesthetic-product/article6267251.ececonditions
  8. ↑ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?symbol=CIPL.BO BusinessWeek
  9. ↑ How a little blue pill changed Cipla’s fortunes | Business Line
  10. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  11. ↑ Cipla to sell MSD’s HIV drug in India | Business Line
  12. ↑ Cipla, Hetero to roll out biosimilar drug | Business Line
  13. ↑ 13.0 13.1 Lua error in package.lua at line 80: module 'strict' not found.
  14. ↑ 14.0 14.1 Lua error in package.lua at line 80: module 'strict' not found.
  15. ↑ 15.0 15.1 Lua error in package.lua at line 80: module 'strict' not found.
  16. ↑ http://www.hbs.edu/businesshistory/emerging-markets/pages/profile-detail.aspx?profile=yhamied
  17. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  18. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  19. ↑ 19.0 19.1 Lua error in package.lua at line 80: module 'strict' not found.
  20. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  21. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  22. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  23. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  24. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  25. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  26. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  27. ↑ 27.0 27.1 Lua error in package.lua at line 80: module 'strict' not found.
  28. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  29. ↑ DBT, Cipla get Thomson Reuters India innovation awards
  30. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  31. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  32. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  33. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  34. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  35. ↑ 35.0 35.1 Lua error in package.lua at line 80: module 'strict' not found.
  36. ↑ Lua error in package.lua at line 80: module 'strict' not found.

External links

Retrieved from "https://infogalactic.com/w/index.php?title=Cipla&oldid=951364"